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Summary
Background Cytomegalovirus reactivation occurs within 6 months in 60–70% of cytomegalovirus-seropositive patients 
after allogeneic haemopoietic stem-cell trans plantation (HSCT), mainly due to immunosuppression associated with 
the procedure. Pre-emptive antiviral therapy reduces incidence of cytomegalovirus disease but can be toxic. To reduce 
the potential for disease and subsequent need for such antiviral drugs, we aimed to assess safety and eﬃ  cacy of a 
cytomegalovirus therapeutic DNA vaccine compared with placebo.
Methods In this exploratory double-blind, placebo-controlled, parallel group, phase 2 trial, up to 80 donor–recipient 
pairs and 80 unpaired recipients undergoing allogeneic HSCT were planned for enrolment at 16 transplant centres in 
the USA. Eligible recipients were cytomegalovirus-seropositive, 18–65 years old, without high-risk primary disease, 
T-cell depletion, previous vaccination for cytomegalovirus, or autoimmune diseases. We randomly allocated participants 
in both parallel groups in a 1:1 ratio to receive a cytomegalovirus therapeutic DNA vaccine (TransVax; Vical, San Diego, 
CA, USA) or placebo before conditioning and at 1, 3, and 6 months after transplantation. The vaccine contains plasmids 
encoding cytomegalovirus glycoprotein B and phosphoprotein 65 formulated with poloxamer CRL1005 and 
benzalkonium chloride. Randomisation was done by sequential allocation based on Pocock and Simon’s method, and 
stratiﬁ ed by site, donor–recipient HLA matching status, and donor’s cytomegalovirus serostatus. The primary outcome 
was the occurrence rate of clinically signiﬁ cant viraemia resulting in initiation of cytomegalovirus-speciﬁ c antiviral 
therapy in the per-protocol assessable population. We assessed rates of adverse events in all participants who received 
at least one dose of vaccine or placebo. This study is registered with ClinicalTrials.gov, number NCT00285259.
Findings We randomly allocated 108 participants (94 HSCT recipients and 14 paired donors) between June 29, 2006, 
and Dec 11, 2009. Enrolment of the paired arm was halted in February 2008 for logistical reasons. Safety was assessed 
in all participants; the eﬃ  cacy population was restricted to 74 unpaired recipients. Groups were balanced for 
demographic and clinical variables. 19 (48%) of 40 vaccine recipients required cytomegalovirus-speciﬁ c antiviral 
therapy, compared with 21 (62%) of 34 controls (p=0·145). However, during follow-up vaccine signiﬁ cantly reduced 
the occurrence and recurrence of cytomegalovirus viraemia and improved the time-to-event for viraemia episodes 
compared with placebo. The vaccine was well-tolerated; only one participant discontinued after an allergic reaction. 
Incidence of common adverse events after HSCT (eg, graft-versus-host disease or secondary infections) did not diﬀ er 
between groups.
Interpretation We show proof of concept for an immunotherapeutic cytomegalovirus vaccine (TransVax) for 
clinically significant viraemia in the HSCT setting. The reported safety and efficacy outcomes support further 
development in a phase 3 trial, notwithstanding a lack of significant reduction in the use of cytomegalovirus-
specific antiviral therapy compared with placebo in this phase 2 trial.
Funding Vical and US National Institute of Allergy and Infectious Diseases.
Introduction
Cytomegalovirus is a β herpesvirus that causes a lifelong 
latent and asymptomatic infection in most individuals 
but can become pathogenic in immunocompromised 
patients such as transplant recipients. Until eﬀ ective 
antiviral therapy became available, nearly 25% of at-risk 
recipients of haemopoietic stem cell transplantations 
died from cytomegalovirus-associated disease in the ﬁ rst 
year after transplantation.1 Patients who are cytomegalo-
virus seropositive can have reactivation of a latent strain 
or reinfection with a new strain and patients who are 
cytomegalovirus seronegative are at risk of primary 
infection after transplantation.2
Virological surveillance and pre-emptive treatment of 
cytomegalovirus infections have substantially reduced 
the incidence and severity of life-threatening illness in 
recipients of allogeneic haemopoietic stem-cell trans-
plants or solid organ transplants. Nonetheless, the rate of 
cytomegalovirus infection or reactivation is 50–80% after 
transplantation.2–5 Cytomegalovirus prophylaxis is limited 
by several shortcomings, which are mainly attributable to 
toxic eﬀ ects associated with current anti-cytomegalovirus 
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therapies.2,6 The ﬁ rst-line antiviral drugs ganciclovir and 
valganciclovir are generally associated with haematological 
toxic eﬀ ects (particularly neutro penia) and delayed 
immune reconstitution. Second-line drugs (ie, foscarnet 
and cidofovir) can cause serious side-eﬀ ects (especially 
nephrotoxic ones). Such toxic eﬀ ects have led to the use 
of a targeted pre-emptive strategy, which allows anti-
cytomegalovirus treatment to be given only to patients 
with clinical evidence of cytomegalovirus viraemia, rather 
than prophylaxis with existing drugs in the setting of 
haemopoietic stem-cell transplantation.7,8
Next-generation prophylactic antiviral drugs are 
undergoing clinical testing and might eﬀ ectively 
reduce the rate of cytomegalovirus infection, although 
a phase 3 study assessing maribavir did not show a 
beneﬁ t in prevention of cytomegalovirus disease when 
started after engraftment.9 The recent introduction of 
sirolimus-based regimens for prophylaxis of graft-versus-
host disease (GVHD) might also result in lower rates of 
cytomegalovirus reactivation.10 However, calcineurin 
inhibitors (tacrolimus or ciclosporin) combined with 
either methotrexate or mycophenolate mofetil continue 
to be the most commonly used regimens for GVHD 
prophylaxis worldwide. In the haemopoietic stem-cell 
transplantation setting, an eﬀ ective vaccine must 
overcome the immunosuppressive eﬀ ects of previous 
chemotherapy and transplant conditioning regimens, as 
well as GVHD prophylaxis and treatment. By contrast 
with the number of new antiviral drugs presently 
undergoing clinical evaluation, there is an unmet need 
for a vaccine that can exploit natural immune response 
mechanisms to control viral replication.
T-cell-mediated immunity is key to control of cyto-
megalovirus replication;11,12 and its consequent impair-
ment resulting from conditioning before allogeneic 
haemopoietic stem-cell transplantation (and secondary 
immune suppression from GVHD prophylaxis) increases 
the risk of cytomegalovirus replication.1 Moreover, the 
increasing use of haploidentical allogeneic haemopoietic 
stem-cell transplantations, which can be used for patients 
who do not have a suitable HLA-matched related or 
unrelated donor, results in an increased risk of serious 
infections (including cytomegalovirus) due to delayed or 
incomplete immune reconstitution.13 Both the initial viral 
load and the rate of increase in cytomegalovirus load are 
correlated with development of serious cyto megalovirus 
disease.14 Furthermore, secondary eﬀ ects of cytomega-
lovirus after haemopoietic stem-cell transplant ations can 
cause poor recovery of cytomegalovirus-speciﬁ c pro-
liferative responses and increased relapse of the 
underlying disease.15
We aimed to assess the safety, immunogenicity, and 
clinical beneﬁ t of an immunotherapeutic cytomegalovirus 
vaccine (TransVax; Vical, San Diego, CA, USA) that 
contains plasmids encoding the surface glycoprotein B 
and tegument phosphoprotein-65. The vaccine is 
formulated with CRL1005 poloxamer and benzalkonium 
chloride, which is a delivery system that enhances gene 
expression in vivo16,17 and increases immune responses 
compared with DNA vaccines formulated in phosphate-
buﬀ ered saline alone.17,18 This formulation has been used 
safely in normal healthy cytomegalovirus-seropositive 
and seronegative adults.19 We did our study in donors and 
cytomegalovirus-seropositive recipients undergoing 
allogeneic haemo poietic stem-cell transplantations for 
various malignant haematological diseases.
Methods
Study design and participants
In our randomised, double-blind, placebo-controlled, 
parallel-group phase 2 trial, we enrolled donor–recipient 
pairs and unpaired recipients undergoing allogeneic 
haemopoietic stem-cell transplantations at 16 participating 
transplant centres in the USA. Transplant recipients were 
eligible if they were cytomegalovirus-seropositive, 
18–65 years old, and had a suitable HLA-matched 
(6/6 A, B, and DR alleles) or HLA-mismatched (5/6 alleles) 
related or unrelated donor willing to undergo peripheral 
blood stem-cell mobilisation with granulocyte colony-
stimulating factor. Use of myeloablative, reduced inten-
sity, and non-myeloablative conditioning regimens 
were permitted before transplantation. Complete ex-vivo 
T-cell depletion of the stem cell graft was a study exclusion 
criterion. Donors were excluded if they had received a 
live-attenuated vaccine within 30 days, previous therapy 
for cytomegalovirus infection, or evidence of congenital 
or acquired immune deﬁ ciencies. Recipients were also 
excluded if their primary disease was deemed as high 
risk or if they had planned T-cell in-vivo depletion with 
alemtuzumab or complete allograft T-cell depletion, 
planned prophylaxis with cytomegalovirus immuno-
globulin or anti-cytomegalovirus therapy, or previous 
diagnoses of autoimmune diseases. We obtained approval 
from institutional review boards before initiation of 
enrolment at every site and all participants provided 
written informed consent.
Randomisation and masking
We randomly allocated participants in a one-to-one ratio 
to receive intramuscular injections of vaccine or placebo. 
We randomly allocated participants dynamically as per 
Pocock and Simon,20 stratiﬁ ed by site, donor–recipient 
HLA matching status, and donor’s cytomegalovirus 
serostatus. Minimisation was accomplished with an 
algorithm based on stratiﬁ cation factors of patients 
already enrolled in the trial. Treatment for each participant 
was assigned and an imbalance score was computed for 
every available treatment; the score was the imbalance 
that would be generated across treatments, taking into 
account stratiﬁ cation factors if that treatment were 
assigned. In general, the treatment with the lowest 
imbalance score was then given preference when 
assigning new participant treatments. Once the donor–
recipient pair or unpaired recipient had been fully 
For the study protocol see 
http://www.vical.com/
CB01-202/default.aspx
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qualiﬁ ed for the trial and all screening activities had been 
completed, a central interactive voice response system 
provided treatment assignment to the site pharmacists, 
who were unmasked to treatment-group allocation. To 
assure that the trial remained masked, the person who 
gave the injections could not be involved in the 
undertaking of any protocol-required procedures or in 
medical care of participants for the duration of the trial. 
Study doctors, staﬀ , and the sponsors were masked until 
the last patient completed follow-up on Nov 19, 2010, and 
the database was closed. No evidence of unmasking was 
noted during monitoring.
Procedures
The investigational vaccine contained plasmids en-
coding cytomegalovirus glycoprotein B and phospho-
protein 65, each at 2·5 mg/mL (ie, 5 mg overall per mL), 
formulated with poloxamer CRL1005 and benzalkonium 
chloride in phosphate-buﬀ ered saline.17–19 Placebo was 
phosphate-buﬀ ered saline. Both vaccines were dosed 
intramuscularly in 1·0 mL. The 5 mg dose was the 
highest dose studied in the dose-escalating phase 1 trial19 
and was restricted by the bulk drug substance con-
centration. In the donor–recipient pair group, donors 
received vaccine or placebo three times before donation 
(2–21 days before collection of peripheral-blood stem 
cells). Recipients of haemopoietic stem-cell transplants 
received vaccine or placebo once before transplantation 
(between days –5 to –3) and three times after trans-
plantation (at 21–42 days, dependent on platelet recovery, 
and on days 84 and 196) and were scheduled for follow-
up and immunogenicity assessments at 56, 84, 126, 196, 
210, and 365 days after transplantation. The dosing 
schedule was designed to optimise immunogenicity 
during periods of greatest risk after transplantation. An 
independent data safety monitoring board assessed the 
safety of the ﬁ rst 20 recipients after their day 56 visit, 
and monitored safety on an ongoing basis.
The primary endpoints were the safety of vaccine 
compared with placebo and rates of cytomegalovirus 
viraemia resulting in initiation of cytomegalovirus-
speciﬁ c antiviral therapy when evidence of viraemia 
indicated its use. Viraemia was deﬁ ned as 500 viral copies 
per mL or more (the lower reporting limit), and was 
assessed with the LightCycler PCR assay (analyte speciﬁ c 
reagents and instrument manufactured by Roche Applied 
Science, Indianapolis, IN, USA). This assay was 
developed and validated in a central laboratory (Mayo 
Figure 1: Trial proﬁ le and participants
*Paired recipients were only assessed for safety; all 14 donors received three doses.
42 randomly allocated to receive vaccine 38 randomly allocated to receive placebo
80 unpaired recipients
42 recipients assessed
       25 received four doses
          7 received three doses
          4 received two doses
          6 received one dose
38 recipients assessed
       23 received four doses
         6 received three doses
         4 received two doses
         5 received one dose
2 excluded
   1 cytomegalovirus negative
   1 died before PCR
4 excluded
    2 cytomegalovirus negative
    2 exclusion violations
40 analysed 34 analysed
12 randomly allocated to receive vaccine 16 randomly allocated to receive placebo
28 paired participants
       14 donors
       14 recipients
6 recipients assessed*
    2 received four doses
    0 received three doses
    3 received two doses
    1 received one dose
8 recipients assessed*
    4 received four doses
    3 received three doses
    0 received two doses
    1 received one dose
119 individuals assessed for eligibility
7 screening failures
112 randomly allocated
4 withdrew before dosing
    2 exclusion violations
    2 withdrew consent
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Clinical Laboratories, Rochester, MN, USA). The PCR 
oligo nucleo tides amplify a segment of the UL54 viral 
polymerase gene. Sites were also allowed to use their 
local laboratories for monitoring of cytomegalovirus 
viraemia and for treatment decisions.
Secondary endpoints included the immunogenicity of 
vaccine compared with placebo by measurement of 
inter feron-γ enzyme-linked immunosorbent spot 
(ELISPOT) responses to phosphoprotein 65 and glyco-
protein B, and glycoprotein B-speciﬁ c antibody concen-
trations measured in an indirect binding IgG ELISA with 
recombinant full-length glycoprotein B protein as the 
coating antigen.19 For recipients of haemopoietic stem-
cell transplants, we recorded time to engraftment, 
occurrence of cytomegalovirus reactivation, time-to 
viraemia (deﬁ ned as number of days from transplantation 
to the date of a positive result in the central laboratory 
assay), occurrence rates of cytomegalovirus-associated 
diseases, acute or chronic GVHD, secondary infections, 
death, and the cumulative number of cytomegalovirus-
speciﬁ c antiviral treatment days. Haemopoietic 
engraftment was deﬁ ned as occurring on the ﬁ rst of 
3 consecutive days when the peripheral blood absolute 
neutrophil count was more than 500 cells per μL. We also 
assessed exploratory endpoints related to cytomegalovirus 
viraemia, such as prevalence of viraemia, time to the 
composite of viraemia and antiviral therapy, and duration 
of viraemia.
Statistical analysis
We calculated the sample size on the basis of the primary 
endpoint of a reduction of cytomegalovirus viraemia in 
recipients. With an equal sample size of 40 individuals 
per group and a historical control reactivation rate of 
60%,1,2,11 there was 70% power to detect a decrease in 
cytomegalovirus infection from 60% to 30%, assuming a 
two-sided α of 0·05.21 We aimed to enrol up to 80 donor–
recipient pairs and 80 unpaired recipients undergoing 
allogeneic haemo poietic stem-cell trans plantations. An 
administrative interim analysis by group was planned 
once all participants had reached day 126, but the study 
masking was maintained until ﬁ nal analysis. We regarded 
diﬀ erences between vaccine and placebo groups as 
signiﬁ cant if p was less than or equal to 0·05 analysed 
with the Wilcoxon rank sum test, the Cochran-Mantel-
Haenszel test (stratiﬁ ed by site), Fisher’s exact test, χ² test, 
or log-rank test as appropriate. We used the Andersen-
Gill generalisation of Cox regression analysis with a 
sandwich variance estimate22 in a post-hoc analysis to 
compare the prevalence of episodes of cytomegalovirus 
viraemia in time between the vaccine and placebo groups. 
This analysis gives an estimate of eﬃ  cacy, and assesses 
the time to more than one episode of cytomegalovirus 
viraemia after adjustment for inter-event correlations. 
The analysis of prevalence and an analysis of the 
composite of clinically signiﬁ cant viraemia and initiation 
of cytomegalovirus-speciﬁ c antiviral therapy, requiring 
both to be present, were exploratory analyses done to 
assess eﬃ  cacy options for a future pivotal study to license 
the vaccine. This approach is often used with phase 2 
data to develop the best statistical approach for phase 3 
trials. All analyses were done with SAS version 9.2.
Vaccine group Placebo group
Haemopoietic stem-cell transplant recipients
n 48 46
Age (years) 49·8 (9·8, 25–63) 48·5 (13·6, 23–72)
Sex (male) 22 (46%) 27 (59%)
Primary diagnosis
Acute myelogenous 
leukaemia
18 (38%) 12 (26%)
Non-Hodgkin lymphoma 9 (19%) 8 (17%)
Acute lymphoblastic 
leukaemia
5 (10%) 8 (17%)
Myelodysplastic syndrome 6 (13%) 6 (13%)
Chronic myelogenous 
leukaemia
3 (6%) 2 (4%)
Hodgkin’s lymphoma 1 (2%) 2 (4%)
Other 6 (13%) 8 (17%)
Karnofsky performance score 88·8 (9·4, 70–100) 86·0 (14·0, 40–100)
Donor cytomegalovirus status
Seropositive 26 (54%) 27 (59%)
Seronegative 22 (46%) 19 (41%)
Donor transplant source
Matched-related donor 29 (60%) 23 (50%)
Matched-unrelated donor 15 (31%) 21 (46%)
Mismatched donor 
(related or unrelated)
4 (8%) 2 (4%)
CD34 cell dose (×10⁶ cells 
per kg)
8·4 (4·6, 2–22)* 7·1 (3·4, 1–16)†
Stem cell source 
Peripheral blood 47 (98%) 44 (96%)
Bone marrow 1 (2%) 2 (4%)
Conditioning regimen
Myeloablative 36 (75%) 35 (76%)
Reduced intensity or 
non-myeloablative
12 (25%) 11 (24%)
Anti-thymocyte globulin in 
conditioning regimen
Yes 4 (8%) 5 (11%)
No 44 (92%) 41 (89%)
Donors
n 6 8
Age (years) 55·2 (9·1, 45–66) 43·9 (13·9, 23–65)
Sex (male) 1 (17%) 2 (25%) 
Cytomegalovirus serostatus
Seropositive 6 (100%) 6 (75%) 
Seronegative 0 2 (25%)
Data are n, mean (SD, range), or n (%). *Data available for 45 (94%) of 48 patients. 
†Data available for 45 (98%) of 46 patients.
Table 1: Baseline characteristics of 94 recipients and 14 donors of 
haemopoietic stem-cell transplants who received at least one dose of 
vaccine or placebo
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This study is registered with ClinicalTrials.gov, number 
NCT00285259.
Role of the funding source
Vical sponsored the study, manufactured the investi-
gational products, and funded most aspects of this 
clinical trial. Vical staﬀ  developed the study design. All 
authors contributed to study design, data collection, 
analysis and interpretation, or writing of the report. All 
authors had full access to to all the data in the study, 
reviewed the report, and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
We enrolled and randomly allocated 112 participants to 
treatment groups between June 29, 2006 and Dec 11, 2009 
and 108 (96%) participants received at least one dose of 
vaccine or placebo (ﬁ gure 1). Although we intended to 
enrol 80 donor–recipient pairs, enrolment in that treat-
ment arm was halted at 14 pairs for logistical reasons in 
February, 2008, and the number of pairs recruited was 
too small for meaningful immunogenicity or eﬃ  cacy 
comparisons between groups.
Overall, 94 cytomegalovirus-seropositive recipients 
of haemopoietic stem-cell transplants and 14 donors 
received vaccine or placebo (ﬁ gure 1, table 1). We noted 
no major imbalances in characteristics between the 
participants randomly assigned to vaccine or to placebo 
(table 1). 71 (75%) of 94 recipients had myeloablative 
conditioning, which was evenly distributed between 
groups, and the remainder had non-myeloablative 
or reduced-intensity conditioning. 53 (56%) of 
94 recipients received transplants from cyto mega lo-
virus-seropositive donors. Dosing compliance was high, 
with most missed doses (77 [20%] of 376 planned doses 
were missed) attributable to delayed platelet recovery or 
premature death.
Of the 80 unpaired recipients recruited, we excluded 
six from further analysis because of inclusion or exclusion 
violations or premature death before viraemia assessment. 
Thus, 74 participants were analysed as part of the per-
protocol assessable population (40 in the vaccine group 
and 34 in the placebo group).
Rates of initiation of cytomegalovirus-speciﬁ c antiviral 
therapy did not diﬀ er between groups in the per-protocol 
assessable population (p=0·145), and treatments lasted 
much the same amount of time (table 2). The rates may 
have been aﬀ ected by the widespread use of results from 
various local laboratories for treatment decisions rather 
than the central laboratory. Conversely, rates of 
cytomegalovirus viraemia on central laboratory measure-
ments were lower in the vaccine group than the placebo 
group (p=0·008) and fewer participants in the vaccine 
group had more than one episode of cytomegalovirus 
viraemia (table 2). On Kaplan-Meier analysis, the time to 
ﬁ rst cyto mega lovirus viraemia was longer in the vaccine 
group than it was in the placebo group, and there was 
Vaccine group (n=40) Placebo group (n=34) p value
Days to haemopoietic engraftment 15 (12–16) 16 (14–18) 0·170
Acute graft-versus host disease ·· ·· 0·152
Grade 0 14 (35%) 7 (21%) ··
Grade I 0 3 (9%) ··
Grade II 24 (60%) 19 (56%) ··
Grade III 1 (3%) 3 (9%) ··
Grade IV 1 (3%) 2 (6%) ··
Chronic graft-versus host disease ·· ·· 0·538
None 12 (30%) 9 (26%) ··
Mild 10 (30%) 6 (18%) ··
Moderate 9 (23%) 10 (29%) ··
Severe 4 (10%) 7 (21%) ··
Not available 5 (13%) 2 (6%) ··
Secondary infection* 34 (85%) 33 (97%) 0·116
Bacterial 28 (70%) 29 (85%) 0·119
Fungal 14 (35%) 14 (41%) 0·585
Viral (excluding cytomegalovirus) 11 (28%) 15 (44%) 0·136
Protozoal 4 (10%) 0 0·120
Other 7 (18%) 10 (29%) 0·225
Data are median (95% CI) or n (%). *Participants might have had more than one occurrence of the same secondary 
infection, but only one event is counted.
Table 3: Selected outcomes in the per-protocol assessable population of unpaired recipients of 
haemopoietic stem-cell transplants
Vaccine group (n=40) Placebo group (n=34) p value
Initiation of pre-emptive CMV-speciﬁ c 
antiviral therapy
19 (47·5%, 32·0–63·0) 21 (61·8%, 45·4–78·1) 0·145
CMV viraemia (≥500 copies per mL) 13 (32·5%, 18·0–47·0) 21 (61·8%, 45·4–78·1) 0·008
CMV episodes ·· ·· 0·017
0 27 (68%) 13 (38%) ··
1 8 (20%) 14 (41%) ··
2 4 (10%) 3 (9%) ··
3 1 (3%) 3 (9%) ··
4 0 1 (3%) ··
Median 0 (1) 1 (1) ··
Median number of days to initial CMV viraemia Not reached 109·5 0·003
Viraemia-free rate at 1 year, % (95% CI) 65·2% (49·7–80·6) 36·8% (20·2–53·5) 0·014*
Mean duration of viraemia in all participants, 
days
10·6 (18·3, 0–68) 19·5 (35·6, 0–181) 0·071
Normalised as percentage time on study 4·9% ( 12·4, 0–63) 7·7% (11·8, 0–49) 0·042
Mean duration of CMV-speciﬁ c antiviral therapy 33·7 (64·1, 0–316) 40·4 (57·7, 0–212) 0·450
Median number of days to a clinical 
composite event†
Not reached 106 0·016
Event-free rate at 1 year, % (95% CI) 71·0% (56·5–85·5) 43·5% (26·7–60·4) 0·015*
CMV-associated disease 3 (7·5%)‡ 3 (8·8%) 1·000
Gastrointestinal 3 (7·5%) 2 (5·9%) ··
CMV pneumonia 1 (2·5%) 1 (2·9%) ··
Data are n (%, 95% CI), n (%), or mean (SD, range), unless otherwise stated. CMV=cytomegalovirus. *Based on a 
Greenwood method.23 †Composite event of CMV viraemia and antiviral therapy. ‡One participant had gastrointestinal 
disease and CMV pneumonia during follow-up.
Table 2: Cytomegalovirus viraemia and cytomegalovirus-speciﬁ c antiviral treatment endpoints in the 
per-protocol assessable population of unpaired recipients of haemopoietic stem-cell transplants after 
1 year follow-up
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evidence to suggest mean duration of viraemia was shorter 
in the vaccine group than the placebo group when the data 
were normalised by percentage time on study (p=0·042; 
table 2). Incidence of biopsy-conﬁ rmed cytomegalovirus-
associated disease did not diﬀ er between groups (table 2).
We assessed safety in 108 participants who received at 
least one dose of vaccine or placebo, although 94 reci-
pients were assessed separately from the 14 donors. All 
recipients developed at least one treatment-emergent 
adverse event during the study. The most frequently 
reported events (in >50% of participants) in both treat-
ment groups were thrombocytopenia, nausea, diarrhoea, 
vomiting, stomatitis, peripheral oedema, rash, headache, 
insomnia, hypomagnesaemia, decreased appetite, fatigue, 
pyrexia, or cough (appendix). Ten (21%) of 48 vaccine 
recipients and ﬁ ve (11%) of 46 placebo recipients had 
injection-site pain (p=0·26). Incidence of treatment-
emergent adverse events was much the same between 
treatment groups. We noted no between-group diﬀ erences 
in the assessments of laboratory tests, vital signs, or 
physical examination results.
39 (81%) of 48 vaccine recipients and 34 (74%) of 
46 placebo recipients had serious adverse events (p=0·393), 
most of which were regarded as unrelated to study product. 
However, site investigators regarded the following serious 
adverse events as possibly related to the investigational 
product: one allergic reaction in a patient also exposed to a 
drug in the same class as a known drug allergen (1 h after 
last dose), one patient with worsening pericardial eﬀ usion 
with cardiac tamponade (1 month after last dose), one 
patient with a subarachnoid haemorrhage from a known 
aneurysm (3 months after last dose), and one patient with 
cytomegalovirus colitis (2 months after the last dose). The 
ﬁ rst three events occurred in participants in the vaccine 
group and the fourth occurred in a participant in the 
control group. After review, the data and safety monitoring 
board regarded only the allergic reaction as possibly 
related to vaccine treatment and that was the only patient 
in the trial who was discontinued due to a treatment-
emergent adverse event. Ten (21%) of 48 vaccine recipients 
and 15 (33%) of 46 placebo recipients died by 1 year after 
transplantation, but the diﬀ erence did not reach 
signiﬁ cance (p=0·196), perhaps because of the small 
sample size. The vaccine safety proﬁ le was therefore much 
the same as that of placebo in transplant recipients and 
the vaccine was well tolerated.
All six donors in the vaccine group and seven of eight 
donors in the placebo group had at least one treatment-
emergent adverse event (injection-site pain in three 
donors in the vaccine group and one donor in the placebo 
group). Nausea, which was reported in three donors in 
the placebo group but no donors in the vaccine group, 
was the only other symptom present in more than two 
donors. Incidence of treatment-emergent adverse events 
were much the same between treatment groups and 
there were no deaths, serious adverse events, or dis-
continuations due to adverse events in donors.
Receipt of vaccine had no eﬀ ect on usual transplant-
related outcomes. The median time to engraftment did 
not diﬀ er between vaccine and placebo groups in the per See Online for appendix
Figure 2: Immunogenicity of vaccine and placebo
Mean (standard error) T-cell responses to overlapping 15-mer phosphoprotein 65 (A) and glycoprotein B (B) 
peptides assessed by interferon γ enzyme-linked immunosorbent spot assay. (C) Geometric mean (95% CI) IgG 
concentrations measured by ELISA, showing glycoprotein B speciﬁ c antibody concentrations. (A and B) Y-axes 
shown on linear scales, although the statistic uses a logarithmic transformation to help normalise the ELISPOT 
data before the analysis. (C) Y-axis shown on a logarithmic scale. SFU=spot-forming units. PBMC=peripheral blood 
mononuclear cells. EU=ELISA units.
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protocol analysis (table 3); only one participant in each 
group had graft failure during the trial. Incidences of 
acute or chronic GVHD were much the same between 
groups. Occurrence of secondary infections did not 
diﬀ er between groups. No infection types (other than 
cytomegalovirus) were signiﬁ cantly more common in 
either group. A much larger study than ours would be 
needed to show signiﬁ cant diﬀ erences in endpoints 
related to the secondary eﬀ ects of cytomegalovirus 
infection in recipients of haemopoietic stem-cell 
transplants.
We did the immunogenicity analysis in the per-protocol 
assessable population. The number of phosphoprotein 
65 interferon-γ-producing T cells was increased, although 
not signiﬁ cantly in a repeated measurements ANOVA, in 
the vaccine group compared with the placebo group at all 
time points after transplantation (ﬁ gure 2).
The number of glycoprotein B interferon-γ-producing 
T cells was much the same at all timepoints (ﬁ gure 2). 
Although not signiﬁ cantly diﬀ erent, the geometric mean 
glycoprotein B antibody concentrations were numerically 
higher in the vaccine group than they were in the placebo 
group at all timepoints after trans plantation (ﬁ gure 2). 
The comparison of the overall curves over time between 
the two groups was made by the F test (an ANOVA test). 
This strategy employs a linear curve model for each 
treatment group, as well as a variance-covariance model 
that incorporates correl ations for all of the observations 
arising from the same participant.
We did exploratory analyses to assess eﬃ  cacy options 
for a pivotal study in the per-protocol assessable popu-
lation. Figure 3 shows the assessment of the prevalence 
of episodes of viraemia every month after trans plan-
tation. The hazard (probability of having events) was 
reduced 53·6% for vaccine compared with placebo 
(ﬁ gure 3). Finally, an analysis of the composite of 
clinically signiﬁ cant viraemia and initiation of 
cytomegalovirus-speciﬁ c antiviral therapy, requiring 
both to be present, showed a reduction in the vaccine 
group compared with placebo after about 6 weeks 
(p=0·016; ﬁ gure 3). Event-free rates were estimated at 
71·0% vs 43·5% at 1 year for the combined endpoint, or 
an eﬃ  cacy of 48·7% (95% CI 8·1–71·3).23,24
Discussion
Compared with placebo, the therapeutic cytomegalovirus 
DNA vaccine TransVax was well tolerated in the 
assessable population in our study, and reduced the 
occurrence, recurrence, duration of episodes of cyto-
megalovirus, viraemia and improved time-to-event at 
1 year follow-up (table 2). However, the rates of clinically 
signiﬁ cant viraemia requiring cytomegalovirus-speciﬁ c 
antiviral therapy after vaccine did not diﬀ er from those 
noted for placebo.
Despite advances in development of antiviral drugs and 
the substantial reduction of disease with pre-emptive 
treatment, cytomegalovirus remains one of the most 
diﬃ  cult-to-treat infections associated with haemopoietic 
stem-cell transplantation. This trial was designed to assess 
a novel vaccine approach in seropositive recipients, who 
are at greatest risk for cytomegalovirus recurrence (panel).2 
Our inclusion and exclusion criteria were chosen to allow 
enrolment of the most representative patients who would 
provide uniform groups; generalisation to larger 
populations will need additional studies. Thera peutic 
vaccination is particularly challenging in recipients of 
haemopoietic stem-cell transplants, whose immune 
systems are purposefully ablated before donor cells are 
transplanted and who remain functionally immuno-
compromised for 6 months or more afterwards. Ideally, 
cytomegalovirus-speciﬁ c immune cells could be trans-
planted directly from a vaccinated donor and the recipient 
would be immediately protected. However, we established 
that donors could not be identiﬁ ed quickly and vaccinated 
Figure 3: (A) Prevalence of cytomegalovirus viraemia at 4 week intervals22 and (B) Kaplan-Meier analysis of 
time to the composite endpoint of viraemia and cytomegalovirus-speciﬁ c antiviral therapy (circles are 
censored events)
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early enough before transplantation; thus, we abandoned 
the matched-pair strategy in favour of vaccination and 
close follow-up of unpaired vaccine recipients. Other 
genetic vaccine approaches, such as with recombinant 
alphaviruses or poxviruses, have shown immunogenicity 
against the cytomegalovirus glycoprotein B or phos-
pho protein 65 antigens in healthy participants.28–30 Our 
vaccine was the ﬁ rst molecular approach tested in 
recipients of haemopoietic stem-cell transplants and might 
have important advantages compared with genetic vaccine 
approaches, including the absence of concerns about the 
potential for spread of replication competent viruses in 
immunosuppressed individuals and reduced potency from 
antivector immune responses after repeated dosing.
Griﬃ  ths and colleagues26 assessed a cytomegalovirus 
vaccine containing recombinant glycoprotein B protein 
and an MF59 adjuvant in adults awaiting kidney or liver 
transplantation. Vaccine reduced duration of viraemia and 
days of ganciclovir treatment compared with placebo only 
in cytomegalovirus-seronegative recipients of organs from 
seropositive donors, despite signiﬁ cant increases in 
glycoprotein B antibodies after vaccination of seronegative 
and seropositive recipients.26 Although humoral immunity 
might have an important role in the seronegative-recipient 
subgroup (which is ~20% of all patients who have solid-
organ transplantations), cell-mediated immunity is crucial 
for protection of transplant recipients from early and late 
reactivation of cyto megalovirus.11,12 The TransVax vaccine 
was designed to not only stimulate antibodies to 
glycoprotein B, which were present at enrolment by 
deﬁ nition in our population, but also T cells to 
glycoprotein B and phosphoprotein 65. Both antigens 
encoded by TransVax (but especially phosphoprotein 65) 
are among the most frequently recognised of all 
cytomegalovirus antigens by both CD4+ and CD8+ T cells 
in healthy cytomegalovirus-seropositive adults who 
maintain lifelong control of the virus.31 In our study, 
vaccine seemed to enhance phosphoprotein 65 cellu lar 
immune responses in these immunosuppressed 
recipients of transplants during the period when they 
were at highest risk for cytomegalovirus disease and thus 
were exposed to the toxicities associated with antiviral 
therapy. Even though the glycoprotein B T-cell assay used 
in our study did not show a signiﬁ cant diﬀ erence between 
groups, cellular responses to glycoprotein B may have an 
important role in protection as well. Results from our 
study complement the ﬁ ndings in the glycoprotein 
B-MF59 study26 and suggest that immunotherapeutic 
vaccines might be useful in all patients at risk of 
cytomegalovirus infection in both the haemopoietic stem 
cell and solid organ transplants settings.
Several outcomes in this trial suggested that the vaccine 
has a notable eﬀ ect in recipients of haemopoietic stem-
cell transplants, primarily in the various measures of 
cytomegalovirus in the blood. Cytomegalovirus infection 
was historically documented by virus isolation and 
cytomegalovirus viraemia is a strong predictor of end-
organ disease and subsequent mortality.32 Increasingly 
sensitive and rapid tests have been developed that form 
the basis for pre-emptive care, which is the most common 
clinical approach to protection from cytomegalovirus 
disease.7 Quantitative establishment of cytomegalovirus 
in the blood precedes the diagnosis of cytomegalovirus 
disease in most patients by several days.33 Even though 
cytomegalovirus disease might no longer be a viable 
endpoint in this population because of the number of 
participants needed to prove eﬃ  cacy,9 the relation 
between initial viral load and risk of cytomegalovirus 
disease shows the integral role that viraemia plays in 
pathogenesis.14,34
The decision to initiate cytomegalovirus-speciﬁ c 
antiviral therapy in the context of viraemia is a strong 
indicator of clinical relevance for this vaccine, particularly 
because of the associated toxic eﬀ ects with use of these 
drugs. However, despite a signiﬁ cant reduction in 
cytomegalo virus viraemia noted in our study, we were 
unable to show a reduction in incidence of initiation of 
antiviral therapy, which we believe was a discrepancy 
caused by the wide variation in institution-speciﬁ c 
algorithms as the basis for antiviral treatment decisions 
and the use of several diﬀ erent local laboratory assays. 
The selection of a consistent viral load that indicates the 
need for antiviral therapy is challenging because of the 
complicated clinical picture, but improvements in assays 
might make this selection possible in the future. Central 
laboratory determination of the onset of viraemia 
Panel: Research in context
Systematic review
We searched PubMed for randomised controlled trials published in English up to 
Nov 13, 2011, that showed proof of concept with a cytomegalovirus vaccine in recipients 
of transplants with the search terms “CMV”, “vaccine”, and “transplant” or any plasmid 
DNA vaccine against any infectious disease target with the search terms “plasmid DNA 
vaccine” and “randomised controlled phase 2 trial”. We did not identify any randomised 
controlled trials on cytomegalovirus vaccine in recipients of haemopoietic stem-cell 
transplants. In 1994, the Towne-strain live-attenuated cytomegalovirus vaccine was 
studied in cytomegalovirus-seronegative transplant recipients of seropositive renal 
allografts and signiﬁ cantly reduced severe cytomegalovirus disease without changing the 
incidence of cytomegalovirus infection.25 We identiﬁ ed one study26 of the glycoprotein 
B-MF59 vaccine, which was tested in liver and renal transplants. We identiﬁ ed one 
phase 2 randomised controlled trial27 testing a plasmid DNA vaccine encoding human 
papillomavirus antigens for eﬃ  cacy against cervical dysplasia. The vaccine promoted 
cervical intraepithelial neoplasia 2/3 lesion resolution in a prospectively deﬁ ned 
population of young women.
Interpretation
The plasmid DNA vaccine TransVax, which includes both glycoprotein B and 
phosphoprotein 65, might provide protection for all cytomegalovirus infections in the 
haemopoietic stem-cell transplantation setting. Our trial is the ﬁ rst proof of concept for a 
cytomegalovirus vaccine in a haemopoietic stem-cell transplantation setting, the third to 
show proof of concept in any transplantation setting, and is the second plasmid DNA 
vaccine to show proof of concept against an infectious disease pathogen.
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combined with the initiation of antiviral therapy in a 
composite endpoint showed a strong vaccine eﬀ ect and 
nearly 50% vaccine eﬃ  cacy; this could be a practical 
clinical endpoint in a pre-emptive antiviral setting for the 
pivotal study. The beneﬁ cial eﬀ ects of TransVax compared 
to placebo, combined with an acceptable safety proﬁ le, 
suggest that this vaccine might ﬁ ll the unmet need for an 
eﬀ ective therapeutic cytomegalovirus vaccine to aid 
clinical care in haemopoietic stem-cell trans plantation 
and warrants further investigation in solid organ 
transplantations.
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